Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of ($0.18), $0.06 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $66.1 million versus the consensus estimate of $60.01 million.

Ironwood now expects to use less than $50 million in cash for operations in 2016, down from previous guidance of less than $70 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.